Neurophysiology

Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021

Retrieved on: 
Thursday, September 9, 2021

The trial enrolled a total of 45 patients with ALS, with unblinded topline data expected in Q4 2021.

Key Points: 
  • The trial enrolled a total of 45 patients with ALS, with unblinded topline data expected in Q4 2021.
  • Thus far the blinded interim data we have seen on the primary and secondary endpoints of our RESCUE-ALS study are very encouraging.
  • We look forward to the unblinded topline readout before the end of the year.
  • Interim blinded efficacy results from the Phase 2 RESCUE-ALS study were presented at the ENCALS 2021 Annual Meeting on May 12, 2021.

Wael Richeh, MD is recognized by Continental Who's Who

Retrieved on: 
Monday, August 16, 2021
Multimedia, Multiple sclerosis, United Presbyterian Church, LSU, SAN, Indian Medical Association, Continental, American Medical Association, American Association, Epilepsy, Professional, Seizure, Patient, National Multiple Sclerosis Society, United Presbyterian Church of North America, Mercer University Health Sciences Center, Neurophysiology, Association, American Association of Neuromuscular & Electrodiagnostic Medicine, Knowledge, Louisiana, Hospital, Damascus University, Medical device, Medicine

SAN ANGELO,Texas, Aug. 16, 2021 /PRNewswire/ --Wael Richeh, MD, is being recognized by Continental Who's Who as a Trusted Neurologist in the field of Medicine and acknowledgment of his exceptional work as a Neurologist at the Shannon Medical Center.

Key Points: 
  • SAN ANGELO,Texas, Aug. 16, 2021 /PRNewswire/ --Wael Richeh, MD, is being recognized by Continental Who's Who as a Trusted Neurologist in the field of Medicine and acknowledgment of his exceptional work as a Neurologist at the Shannon Medical Center.
  • As a trusted board-certified neurologist, Dr. Richeh has accrued 19 years of professional experience in his field.
  • An academic scholar, Dr. Richeh's acclaimed career began after he earned his MD in a 7-year program at Damascus University.
  • Dr. Richeh dedicates this honorable recognition to Carol Guttierez, MD (mentor and program director at LSU), and Jean Englund, MD (Chair Neurology at LSU).

CVRx to Present at the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Neuroscience, Neurophysiology, Genuity, Neuromodulation, Autonomic, Heart

MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx , Inc. (CVRx), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced thatthe management team will participate in the Canaccord Genuity 41st Annual Growth Conference onThursday, August 12, 2021.

Key Points: 
  • MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx , Inc. (CVRx), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced thatthe management team will participate in the Canaccord Genuity 41st Annual Growth Conference onThursday, August 12, 2021.
  • The Company is scheduled to present at the conference at11:00 am Eastern Timethe same day via webcast.
  • A live audio webcast of the conference presentation will be available online at the investor relations page of the Companys website at ir.cvrx.com .
  • The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Brain Scientists Unveil Wiring Diagram Containing 200,000 Cells And Nearly Half Billion Connections In Tiny Piece Of A Mouse's Brain

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Neuroscience, Biology, Neurophysiology, Nervous system, Neurology, Psychiatry

Google contributed storage and computing engine support through Google Cloud, and an open source visualization tool Neuroglancer through Google Research.

Key Points: 
  • Google contributed storage and computing engine support through Google Cloud, and an open source visualization tool Neuroglancer through Google Research.
  • But the dataset is also valuable to the neuroscience field both for scientists seeking to understand how the brain conveys information along defined circuits, and for biomedical researchers wanting to treat brain disorders where wiring or connections are altered.
  • "We're basically treating a brain circuit as a computer, and we asked three questions: What does it do?
  • said R. Clay Reid , M.D., Ph.D., Senior Investigator at the Allen Institute and one of the lead scientists of MICrONS.

$1.3 Billion Worldwide Intracranial Pressure (ICP) Monitoring Devices Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Infectious diseases, Health, Medical devices, Branches of biology, Neurotrauma, Medical signs, Intracranial pressure, Neurophysiology, Ventricular system, ICP

The "Intracranial Pressure (ICP) Monitoring Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intracranial Pressure (ICP) Monitoring Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Intracranial Pressure (ICP) Monitoring Devices estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$1.9 Billion by 2027, growing at a CAGR of 5.3% over the period 2020-2027.
  • Invasive, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$1.7 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $365 Million, While China is Forecast to Grow at 8.1% CAGR
    The Intracranial Pressure (ICP) Monitoring Devices market in the U.S. is estimated at US$365 Million in the year 2020.

BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, TMS

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

Dominican Republic National Baseball Team Turns to STRIVE to Optimize Performance at the Tokyo Olympic Games

Retrieved on: 
Tuesday, July 27, 2021
Baseball, General Sports, Sports, Health, Events, Concerts, Other Sports, Fitness & Nutrition, Entertainment, Branches of biology, Anatomy, Electrodiagnosis, Electrophysiology, Neurophysiology, Neurotechnology, Electromyography, Skeletal muscle, Quadriceps femoris muscle

STRIVE , the only platform proven to optimize muscle performance for elite athletes and teams, today announced that the Dominican Republics national baseball team has been using the STRIVE platform during training for the Olympic Games in Tokyo, Japan.

Key Points: 
  • STRIVE , the only platform proven to optimize muscle performance for elite athletes and teams, today announced that the Dominican Republics national baseball team has been using the STRIVE platform during training for the Olympic Games in Tokyo, Japan.
  • STRIVE has enabled the teams training staff to monitor players muscle performance in all active settings in the lead-up to the 2021 Olympic Games: practice, conditioning, and in-game.
  • The STRIVE platform gives us technology to add value to the players understanding of their body.
  • STRIVEs world-leading electromyography (EMG) technology enables the Dominican national team to monitor the muscle activation of its players hamstrings, glutes, and quadriceps.

Axogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Neuroscience, Anatomy, AxoGen, Neurophysiology, Canaccord Genuity, Genuity, Neuroregeneration, Nerve

ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Canaccord Genuity 41st Annual Growth Conference.

Key Points: 
  • ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Canaccord Genuity 41st Annual Growth Conference.
  • The presentation will be webcast live and can be accessed through the Investors page at www.axogeninc.com .
  • Axogen (AXGN) Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
  • The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.

CVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Neuroscience, Neurotechnology, Neuromodulation, Neurophysiology, Neuropsychology, Pain

MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (CVRx), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter financial and operating results after market close on Wednesday, August 4, 2021.

Key Points: 
  • MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (CVRx), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter financial and operating results after market close on Wednesday, August 4, 2021.
  • The Company will host a conference call to review its results at5:30 p.m. Eastern Timethe same day.
  • To listen to a live webcast, please visit the Investors section of the CVRx website at: ir.cvrx.com/investor-relations.
  • The webcast replay will be available on the CVRx website for 12 months following completion of the call.

ChiliSleep™ Announces Sleep Tech Collaboration With Cincinnati Reds and Seattle Mariners

Retrieved on: 
Tuesday, July 20, 2021
Baseball, MEN, Sports, General Health, General Sports, Consumer, Fitness & Nutrition, Retail, Other Consumer, Women, Health, Home Goods, Branches of biology, Biology, Neuroscience, Sleep, Kryo, Sleep disorders, Neurophysiology

Kryo, Inc., the parent company of sleep technology brand ChiliSleep, today announced an innovative sports science collaboration with both the Cincinnati Reds and the Seattle Mariners Major League Baseball teams.

Key Points: 
  • Kryo, Inc., the parent company of sleep technology brand ChiliSleep, today announced an innovative sports science collaboration with both the Cincinnati Reds and the Seattle Mariners Major League Baseball teams.
  • This season, players have the opportunity to use the OOLER sleep system, which is ChiliSleeps advanced, temperature-regulated sleep tech that decreases body temperature to trigger deep sleep for players at home and on the road.
  • Both the Reds and Mariners front offices were looking to implement a new tool to help players train and perform at their best.
  • ChiliSleep is a sleep technology brand that optimizes health and wellness through clinically researched and drug-free sleep therapies to improve sleep quality.